NO20060506L - Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter - Google Patents

Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter

Info

Publication number
NO20060506L
NO20060506L NO20060506A NO20060506A NO20060506L NO 20060506 L NO20060506 L NO 20060506L NO 20060506 A NO20060506 A NO 20060506A NO 20060506 A NO20060506 A NO 20060506A NO 20060506 L NO20060506 L NO 20060506L
Authority
NO
Norway
Prior art keywords
drugs
preparation
sulfonamide derivatives
indol
diastereomers
Prior art date
Application number
NO20060506A
Other languages
English (en)
Norwegian (no)
Inventor
Alberto Dordal Zueras
Xavier Codony Soler
Vidal Ramon Merce
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of NO20060506L publication Critical patent/NO20060506L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20060506A 2003-07-30 2006-01-31 Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter NO20060506L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301808A ES2222830B1 (es) 2003-07-30 2003-07-30 Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
PCT/EP2004/008513 WO2005013979A1 (en) 2003-07-30 2004-07-29 Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators

Publications (1)

Publication Number Publication Date
NO20060506L true NO20060506L (no) 2006-01-31

Family

ID=34130542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060506A NO20060506L (no) 2003-07-30 2006-01-31 Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter

Country Status (23)

Country Link
US (1) US7414070B2 (de)
EP (1) EP1648444B1 (de)
JP (1) JP2007500167A (de)
KR (1) KR20060036457A (de)
CN (1) CN1832739A (de)
AR (1) AR045158A1 (de)
AT (1) ATE432698T1 (de)
AU (1) AU2004262487A1 (de)
BR (1) BRPI0413001A (de)
CA (1) CA2534136A1 (de)
DE (1) DE602004021383D1 (de)
EC (1) ECSP066323A (de)
ES (2) ES2222830B1 (de)
IL (1) IL172750A0 (de)
MX (1) MXPA06001130A (de)
NO (1) NO20060506L (de)
NZ (1) NZ545298A (de)
PE (1) PE20050352A1 (de)
PT (1) PT1648444E (de)
RU (1) RU2006105791A (de)
TW (1) TW200510433A (de)
WO (1) WO2005013979A1 (de)
ZA (1) ZA200600418B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018861A1 (de) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Liganden wie Sulfonamidederivaten bei wirkstoffinduzierter Gewichtszunahme
ES2358288T3 (es) 2007-08-01 2011-05-09 Laboratorios Del Dr. Esteve S.A. Combinación de al menos dos ligandos de 5ht6.
EP2053052A1 (de) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Verfahren zur Herstellung von 6-substituiertem Imidazo[2,1-b]thiazol-5-sulfonylhalogenid
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
DE19753522A1 (de) * 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2002167376A (ja) * 2000-11-30 2002-06-11 Mercian Corp 血管内皮細胞増殖因子発現抑制作用を有するインドール誘導体及びその用途
ATE340795T1 (de) 2001-01-30 2006-10-15 Lilly Co Eli Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
US6488243B2 (en) * 2001-04-06 2002-12-03 Seong Tae Kim Bag holder for hanging on rims of miscellaneous items
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
JP2006525972A (ja) * 2003-05-09 2006-11-16 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 食物摂取障害の予防および/または治療用の医薬品製造のためのスルホンアミド誘導体の使用

Also Published As

Publication number Publication date
KR20060036457A (ko) 2006-04-28
ZA200600418B (en) 2007-03-28
US20070185207A1 (en) 2007-08-09
NZ545298A (en) 2008-06-30
CN1832739A (zh) 2006-09-13
BRPI0413001A (pt) 2006-09-26
PT1648444E (pt) 2009-09-03
RU2006105791A (ru) 2007-09-20
AR045158A1 (es) 2005-10-19
DE602004021383D1 (de) 2009-07-16
ECSP066323A (es) 2006-08-30
TW200510433A (en) 2005-03-16
CA2534136A1 (en) 2005-02-17
AU2004262487A1 (en) 2005-02-17
WO2005013979A1 (en) 2005-02-17
ES2222830A1 (es) 2005-02-01
IL172750A0 (en) 2006-04-10
PE20050352A1 (es) 2005-06-12
US7414070B2 (en) 2008-08-19
EP1648444A1 (de) 2006-04-26
MXPA06001130A (es) 2006-04-24
ATE432698T1 (de) 2009-06-15
JP2007500167A (ja) 2007-01-11
EP1648444B1 (de) 2009-06-03
ES2327846T3 (es) 2009-11-04
ES2222830B1 (es) 2006-02-16

Similar Documents

Publication Publication Date Title
NO20060682L (no) Indol-6 sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
NO20060865L (no) Indol-5-YL sulfonamid derivater, deres fremstilling og deres anvedelse 5-HT-6 som modulatorer
NO20060342L (no) 1-sulfonylindol derivater, deres fremstilling og deres andvendelse som 5-HT6 ligander
NO20081844L (no) Terapeutiske forbindelser
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
UY27350A1 (es) Azaindoles
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
NO20060908L (no) Substituerte tazol-benzoisotiazoldioksidderivater, deres fremstilling og anvendelse
NO20092103L (no) Tetrahydrocyklopenta[B]indolforbindelser som androgenreseptormodulatorer
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20055977L (no) Nye benzimidazolderivater
NO20091766L (no) Spiro-piperidinderivater
ATE424822T1 (de) Tetrahydro-beta-karbolin-sulfonamid-derivate als 5-ht6-liganden
SE0402925D0 (sv) Novel Compounds
NO20060155L (no) Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
NO20055492L (no) Anvendelse av sulfonamidderivater for fremstilling av et medikament for profylakse og/eller behandling av lidelser ved matinntak
DE60208694D1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
NO20060506L (no) Indol-7-yl sulfonamid derivater, deres fremstilling og deres anvendelse i medikamenter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application